162 related articles for article (PubMed ID: 34567960)
1. Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer.
Clemons M; Liu M; Stober C; Pond G; Jemaan Alzahrani M; Ong M; Ernst S; Booth C; Mates M; Abraham Joy A; Aseyev O; Blanchette P; Vandermeer L; Tu M; Thavorn K; Fergusson D;
J Bone Oncol; 2021 Oct; 30():100388. PubMed ID: 34567960
[TBL] [Abstract][Full Text] [Related]
2. A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.
Clemons M; Ong M; Stober C; Ernst S; Booth C; Canil C; Mates M; Robinson A; Blanchette P; Joy AA; Hilton J; Aseyev O; Pond G; Jeong A; Hutton B; Mazzarello S; Vandermeer L; Kushnir I; Fergusson D;
Eur J Cancer; 2021 Jan; 142():132-140. PubMed ID: 33023785
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer.
Tu MM; Clemons M; Stober C; Jeong A; Vandermeer L; Mates M; Blanchette P; Joy AA; Aseyev O; Pond G; Fergusson D; Ng TL; Thavorn K
Curr Oncol; 2021 May; 28(3):1847-1856. PubMed ID: 34068083
[TBL] [Abstract][Full Text] [Related]
4. Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers.
Alzahrani M; Stober C; Liu M; Awan A; Ng TL; Pond G; Alshamsan B; Vandermeer L; Clemons M
Support Care Cancer; 2022 May; 30(5):3977-3984. PubMed ID: 35059864
[TBL] [Abstract][Full Text] [Related]
5. Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey.
Alzahrani M; Clemons M; Sienkiewicz M; Shrem NS; McGee SF; Vandermeer L; Sehdev S; Savard MF; Awan A; Canil C; Hutton B; Pond G; Saunders D; Ng T
Support Care Cancer; 2021 Nov; 29(11):6903-6912. PubMed ID: 34023950
[TBL] [Abstract][Full Text] [Related]
6. Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.
Anton A; Wong S; Shapiro J; Weickhardt A; Azad A; Kwan EM; Spain L; Gunjur A; Torres J; Parente P; Parnis F; Goh J; Semira MC; Gibbs P; Tran B; Pezaro C
Eur J Cancer; 2021 Nov; 157():485-492. PubMed ID: 34344533
[TBL] [Abstract][Full Text] [Related]
7. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events.
Smith MR; Coleman RE; Klotz L; Pittman K; Milecki P; Ng S; Chi KN; Balakumaran A; Wei R; Wang H; Braun A; Fizazi K
Ann Oncol; 2015 Feb; 26(2):368-74. PubMed ID: 25425475
[TBL] [Abstract][Full Text] [Related]
8. Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases.
Lobo-Martins S; Ferreira AR; Mansinho A; Casimiro S; Leitzel K; Ali S; Lipton A; Costa L
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32722128
[TBL] [Abstract][Full Text] [Related]
9. Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey.
AlZahrani M; Clemons M; Vandermeer L; Sienkiewicz M; Awan AA; Hutton B; Pond GR; Ng TL
J Bone Oncol; 2021 Feb; 26():100339. PubMed ID: 33294318
[TBL] [Abstract][Full Text] [Related]
10. Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16).
Mark M; Thürlimann B; Ribi K; Schär C; Dietrich D; Cathomas R; Zürrer-Härdi U; von Briel T; Anchisi S; Bohanes P; Blum V; von Burg P; Mannhart M; Caspar CB; von Moos R
J Bone Oncol; 2020 Apr; 21():100273. PubMed ID: 31970055
[TBL] [Abstract][Full Text] [Related]
11. Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands.
Kuppen MCP; Westgeest HM; van den Eertwegh AJM; van Moorselaar RJA; van Oort IM; Tascilar M; Mehra N; Lavalaye J; Somford DM; Aben KKH; Bergman AM; de Wit R; van den Bergh ACMF; de Groot CAU; Gerritsen WR
Clin Genitourin Cancer; 2022 Feb; 20(1):43-52. PubMed ID: 34848157
[TBL] [Abstract][Full Text] [Related]
12. Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
Phillips WJ; Saad F; Leigh J; Jooya A; Webber C; Morgan S; MacRae R; Bourque JM; Tanuseputro P; Ong M
Oncologist; 2024 Mar; ():. PubMed ID: 38527096
[TBL] [Abstract][Full Text] [Related]
13. Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis.
Ibrahim MF; Mazzarello S; Shorr R; Vandermeer L; Jacobs C; Hilton J; Hutton B; Clemons M
Ann Oncol; 2015 Nov; 26(11):2205-13. PubMed ID: 26122727
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
15. Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases.
McKay R; Haider B; Duh MS; Valderrama A; Nakabayashi M; Fiorillo M; Ristovska L; Wen L; Kantoff P
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):276-282. PubMed ID: 28220804
[TBL] [Abstract][Full Text] [Related]
16. Practical update for the use of bone-targeted agents in patients with bone metastases from metastatic breast cancer or castration-resistant prostate cancer.
Southcott D; Awan A; Ghate K; Clemons M; Fernandes R
Curr Oncol; 2020 Aug; 27(4):220-224. PubMed ID: 32905286
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
18. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
[TBL] [Abstract][Full Text] [Related]
19. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
Sartor O; Coleman R; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Vogelzang NJ; O'Bryan-Tear CG; Shan M; Bruland ØS; Parker C
Lancet Oncol; 2014 Jun; 15(7):738-46. PubMed ID: 24836273
[TBL] [Abstract][Full Text] [Related]
20. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
